India's Cipla gets tentative U.S. nod for HIV tablets
MUMBAI (Reuters) - Indian drugmaker Cipla has received a tentative U.S. FDA approval for its HIV treatment tablets, which have a combination of lamivudine, nevirapine and zidovudine drugs, the drug regulator's website showed.
Cipla sells the combination drug under the brand name 'Duovir N' outside the United States.
The company plans to use a different brand name in the U.S. for this drug, S. Radhakrishnan, a director on Cipla board told Reuters.
(Reporting by Kaustubh Kulkarni; Editing by Anupama Dwivedi)
- Tweet this
- Share this
- Digg this
- Tesco scraps profit outlook as accounting black hole deepens
- Canada's parliament attacked, soldier fatally shot nearby |
- Hungary plans new tax on Internet traffic, public calls for rally
- Canada PM vows crackdown after capital shocked by fatal attacks |
- UKIP on course to win second parliamentary seat - poll